Shares of regenerative medicine stem cell companies are reacting to visibility and sentiment issues as stocks are acting as a thermometer of investor emotion. Read more…
The 6 W’s: Who, what, where, when, why and what of it… Read more…
A net loss of $4M or $0.29 per share Read more…
Data at 2 years post-op met primary endpoints Read more…
The 6 W’s: Who, what, where, when, why and what of it Read more…
Firm aims to exploit human amniocyte-derived cell lines through new vaccine development partnerships Read more…
ASTM has reached agreement with the FDA on the Special Protocol Assessment (SPA) Read more…
The 6 W’s: Who, what, where, when, why and what of it… Read more…
Judge Royce Lamberth, chief of the federal court in Washington is throwing out a lawsuit challenging the Obama administration’s funding of embryonic stem cell research. Read more…
Cardio3 BioSciences, the maker of an experimental stem-cell heart therapy called C-Cure is …. (hoping) raising Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.